Cargando…

Intestinal Dysbiosis, the Tryptophan Pathway and Nonalcoholic Steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) progresses from simple steatosis to steatohepatitis (NASH), which may then progress to the development of cirrhosis and hepatocarcinoma. NASH is characterized by both steatosis and inflammation. Control of inflammation in NASH is a key step for the preventio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jiezhong, Vitetta, Luis, Henson, Jeremy D, Hall, Sean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829707/ https://www.ncbi.nlm.nih.gov/pubmed/35153490 http://dx.doi.org/10.1177/11786469211070533

Ejemplares similares

The intestinal microbiota and improving the efficacy of COVID-19 vaccinations
por: Chen, Jiezhong, et al.
Publicado: (2021)

Effects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways
por: Chen, Jiezhong, et al.
Publicado: (2019)

Gut Dysbiosis Could Be a Major Factor for the Effects of Low-Grade Endotoxemia in COVID-19 Comment on: Low-Grade Endotoxemia and Thrombosis in COVID-19
por: Chen, Jiezhong, et al.
Publicado: (2022)

Intestinal Dysbiosis and Tryptophan Metabolism in Autoimmunity
por: Brown, Josephine, et al.
Publicado: (2020)

Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions
por: Henson, Jeremy D., et al.
Publicado: (2022)

Prebiotics Progress Shifts in the Intestinal Microbiome That Benefits Patients with Type 2 Diabetes Mellitus
por: Vitetta, Luis, et al.
Publicado: (2023)

The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis
por: Xiang, Hui, et al.
Publicado: (2022)

Gut Dysbiosis and the Intestinal Microbiome: Streptococcus thermophilus a Key Probiotic for Reducing Uremia
por: Vitetta, Luis, et al.
Publicado: (2019)

Enhancing Endocannabinoid Control of Stress with Cannabidiol
por: Henson, Jeremy D., et al.
Publicado: (2021)

Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
por: Chen, Jiezhong, et al.
Publicado: (2020)

Modulation of Gut Microbiota for the Prevention and Treatment of COVID-19
por: Chen, Jiezhong, et al.
Publicado: (2021)

The Role of Butyrate in Attenuating Pathobiont-Induced Hyperinflammation
por: Chen, Jiezhong, et al.
Publicado: (2020)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease
por: Saltzman, Emma T., et al.
Publicado: (2018)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

The Brain–Intestinal Mucosa–Appendix– Microbiome–Brain Loop
por: Vitetta, Luis, et al.
Publicado: (2018)

Perna canaliculus and the Intestinal Microbiome
por: Saltzman, Emma Tali, et al.
Publicado: (2017)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Commensal bacterial metabolites may strengthen the effect of anti-IL6 treatment for COVID-19
por: Chen, Jiezhong, et al.
Publicado: (2021)

Gut-brain axis in the neurological comorbidity of COVID-19
por: Chen, Jiezhong, et al.
Publicado: (2021)

Immunological Tolerance and Function: Associations Between Intestinal Bacteria, Probiotics, Prebiotics, and Phages
por: Vitetta, Luis, et al.
Publicado: (2018)

Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
por: Luther, Jay, et al.
Publicado: (2015)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

Complement Alternative Pathway Activation in Human Nonalcoholic Steatohepatitis
por: Segers, Filip M., et al.
Publicado: (2014)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis
por: Tincopa, Monica A.
Publicado: (2020)

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

MicroRNAs and Nonalcoholic Steatohepatitis: A Review
por: Morishita, Asahiro, et al.
Publicado: (2023)

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?
por: Ali, Mahmoud A, et al.
Publicado: (2017)

Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences
por: Joshi-Barve, Swati, et al.
Publicado: (2015)

Relationship between intestinal flora and inflammatory factors in patients with nonalcoholic steatohepatitis
por: Zhang, Jian, et al.
Publicado: (2018)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future
por: Gitto, S., et al.
Publicado: (2015)

Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
por: Yoon, In Cheol, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ko6c2mk1b5jt7g6nvvahsqj9ov